| 18.13 -2.71 (-13%) | 10-06 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 29.02  |
1-year : | 33.93 |
| Resists | First : | 24.84 |
Second : | 29.04 |
| Pivot price | 21.63 |
|||
| Supports | First : | 18.05 |
Second : | 15.02 |
| MAs | MA(5) : | 20.46 |
MA(20) : | 22.17 |
| MA(100) : | 20  |
MA(250) : | 0 | |
| MACD | MACD : | -1 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 19.3 |
D(3) : | 26.5 |
| RSI | RSI(14): 35.7 |
|||
| 52-week | High : | 29.04 | Low : | 15.1 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ODTX ] has closed below the lower bollinger band by 4.8%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 20.86 - 20.98 | 20.98 - 21.09 |
| Low: | 17.81 - 17.93 | 17.93 - 18.03 |
| Close: | 17.96 - 18.15 | 18.15 - 18.32 |
Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on discovering and developing novel treatments for autoimmune and inflammatory diseases. Its diverse pipeline features several key drug candidates: OD-001, an oral small molecule that inhibits receptor-interacting protein kinase 2, which is currently in Phase 2a clinical trials for ulcerative colitis. Also included is OD-002, an oral small molecule SLC15A4 inhibitor engineered to prevent harmful inflammatory responses driven by TLR7/8/9-mediated activation of interferon regulatory factor 5 (IRF5). Another program, OD-003, is a protein therapeutic designed to selectively agonize tumor necrosis factor receptor 2 on T regulatory cells. Further assets in its portfolio comprise a bispecific antagonist targeting TSLP and IL-33, an oral small molecule functioning as an interleukin-1 receptor-associated kinase 4 scaffolding inhibitor, and a separate small molecule inhibitor specifically targeting IRF5. The company was founded in 2021 and is headquartered in Boston, Massachusetts.
Tue, 06 Oct 2026
More ulcerative colitis trial results will be shared Oct. 20, with extra data in a webcast. - Stock Titan
Mon, 05 Oct 2026
Odyssey Therapeutics, Inc. (NASDAQ:ODTX) Stock Has Consensus Target Price of $35.75 According to Brokerages - MarketBeat
Tue, 22 Sep 2026
H.C. Wainwright Keeps Their Buy Rating on Odyssey Therapeutics, Inc. (ODTX) - The Globe and Mail
Thu, 17 Sep 2026
Odyssey Therapeutics, Inc.(NasdaqCM: ODTX) added to Russell 2500 Value Benchmark - marketscreener.com
Wed, 16 Sep 2026
Odyssey Therapeutics to Participate in Stifel 2026 Virtual Immunology and Inflammation Forum - GlobeNewswire
Sun, 13 Sep 2026
Odyssey Therapeutics (ODTX) Banks Two More Years As Trials Multiply - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 48 (M) |
| Held by Insiders | 2.366e+007 (%) |
| Held by Institutions | 6 (%) |
| Shares Short | 1,990 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.5027e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -156 % |
| Return on Assets (ttm) | 392.9 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 99000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -3.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -132 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 2.25e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|